Clinical Trials Browser

OTHER × MLN 8237 × Thoracic × Clear all

NCT04085315 2024-06-10

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Phase 1 Recruiting

Lung Cancer Metastatic

NCT04479306 2024-06-04

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02293005 2022-10-04

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Phase 2 Completed

28 enrolled 11 charts

Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

NCT01471964 2018-05-17

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Phase 1/2 Terminated

Non-small Cell Lung Cancer Metastatic